GT Medical Technologies

GT Medical Technologies announced $100M in Series E financing on June 9, 2026. GT Medical Technologies raised a $100 million Series E led by new investor Viking Global Investors to accelerate commercial and operational initiatives for its GammaTile brain tumor therapy.

Round details

The financing includes backing from Viking Global Investors, MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners, FemHealth Ventures. The company did not publish a valuation with the announcement.

• Round: Series E
• Capital announced: $100M

How the company plans to use the capital

GT Medical Technologies said the funds will accelerate investments across commercial and operational initiatives, and will also support continued expansion of its recently initiated BRIDGES randomized controlled trial in newly diagnosed glioblastomas.

Why this matters for GTM teams

The round was led by a new investor, Viking Global Investors, with participation from existing investors, and the company said the funds will go toward commercial and operational initiatives and expansion of its BRIDGES randomized controlled trial.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: GT Medical Technologies Series E announcement.